Navigation Links
Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adverse cardiac events and no protocol-defined stent thrombosis. The next-generation Medtronic (NYSE:MDT) Endeavor(R) Resolute drug-eluting stent system with new BioLinx(TM) polymer is designed to address the special needs of patients who have complex medical conditions and is engineered to match the duration of drug delivery with the longer healing duration often required by these patients.

In clinical results at nine months, the Endeavor RESOLUTE trial showed no Target Lesion Revascularization (TLR), no Target Vessel Revascularization (TVR) and a Major Adverse Cardiac Event (MACE) rate of just 7.0%. Of the trial's 130 patients, 129 (99.2%) received clinical follow-up, and 95 had angiographic follow-up. In-stent late lumen loss, the study's primary endpoint, was 0.22 mm, while in-segment late loss was 0.12 mm. In-stent Angiographic Binary Restenosis (ABR) was 1.0% percent and in-segment ABR was 2.1%.

"What is most impressive about these results is that they occurred in a patient population with complex and challenging characteristics," said Dr. Meredith, the principal investigator of the trial, noting that the average lesion length in the RESOLUTE trial was 15.5 mm and nearly 82% of enrolled patients were classified as having challenging B2/C lesions. "The RESOLUTE trial enrolled a high percentage of patients with lesions that are difficult to treat, including small vessels and long lesions, and these results are extremely promising. Zotarolimus continues to be a very potent drug in preventing restenosis while the new BioLinx polymer appears to be delivering the drug as intended."

Endeavor Resolute leverage s the strengths of the Endeavor stent and introduces BioLinx, a proprietary, biocompatible polymer designed by Medtronic scientists. BioLinx is different from other polymers in that its outer surface is hydrophilic (water friendly), which leads to high biocompatibility with the body. At the same time, the interior of the polymer is hydrophobic, which helps to control the drug release. Some polymers can produce an inflammatory response within the blood vessel. This can contribute to thrombosis or occlusion of the artery - outcomes that are more pronounced in patients with difficult lesions or complex medical conditions. BioLinx is a non-inflammatory polymer blend that mimics the make-up of a cell membrane to maintain biocompatibility.

"The Medtronic drug-eluting stent product pipeline is extremely strong, with clinical trial results that demonstrate an impressive combination of safety and effectiveness," said Scott Ward, president of the CardioVascular business at Medtronic. "Endeavor RESOLUTE is designed to complement Endeavor and provide physicians with a compelling choice of drug-eluting stents to match the specific needs of their patients. Medicine is very personal and these data clearly reinforce that we are achieving our mission of providing doctors with the products they need to provide the best possible care for their patients with coronary artery disease."

Two articles on the Medtronic RESOLUTE trial and the Endeavor Resolute stent will be published this week in the medical journal EuroIntervention. They are: "The next-generation Endeavor(TM) Resolute stent: 4-month clinical and angiographic results from the Resolute first-in-man trial," authored by Dr. Meredith and others; and "The Next Generation ENDEAVOR RESOLUTE Stent: Role of the BioLinx(TM) Polymer System," authored by Kishore Udipi, Medtronic Director of Polymer Research, and others.

The Endeavor Resolute stent is not yet approved in any country. Data from the Endeavor RESOLUTE cl inical trial will be used to support the CE Mark application.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Caution: The Endeavor Drug-Eluting Coronary Stent is an investigational device with an investigational drug (Zotarolimus) and exclusively for clinical investigation in the United States.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results.

Contact

Medtronic, Inc.
Public Relations:
Yvan Deurbroeck, 41 79 249 3670
or
Scott Papillon, 707-591-7367
or
Investor Relations:
Jeff Warren, 763-505-2696


'"/>




Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a trusted advisor to the U.S. ... industry white paper, entitled Barriers to Adoption of the ERA and EFT Transactions ...
(Date:9/19/2017)... ... , ... Driving Dynamics Inc., announced today it has been selected as a ... of its mission to continually monitor the training marketplace for the best providers of ... Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular ... ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been ... a trusted, well-respected brand reliant on the healing properties of plants, a proven ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... the Davidson Fellows Scholarship on September 27 at a reception in Washington D.C. ... Engineering, Mathematics, Literature and Music. , “I am honored to be a Davidson ...
Breaking Medicine News(10 mins):